Recent Press Releases

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress HS is a...

SIRTURO® (bedaquiline) Wins UK Prix Galien Award for Most Innovative Orphan Drug

SIRTURO® (bedaquiline) Wins UK Prix Galien Award for Most Innovative Orphan Drug The first new medicine for tuberculosis in over 40 years has received the 2014 UK Prix Galien – regarded as...

FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy

FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and...

VEXIM to Initiate Clinical Study to Support Planned 510(k) Application to Market SpineJack® in the United States

VEXIM to Initiate Clinical Study to Support Planned 510(k) Application to Market SpineJack® in the United States

CEO

Regulatory News:

Abbott Celebrates the Power of Health and Achievement as First-Ever Title Sponsor of World Marathon Majors

SERIES WILL BE RENAMED ABBOTT WORLD MARATHON MAJORS STARTING IN 2015

ABBOTT PARK, Ill., Oct.

Hikma update on colchicine

Hikma update on colchicine London, 10 October 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group,...

Hikma update on colchicine

Hikma update on colchicine London, 10 October 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group,...

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA Company Receives Additional Paragraph IV Notice BETHESDA, Md., Oct. 9, 2014 (GLOBE NEWSWIRE) --...

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia Additional Global Regulatory Filings Reinforce Commitment to Addressing...

FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma

FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma This approval extends the benefit of VELCADE for mantle cell lymphoma (MCL) to...

Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options

Impax To Acquire Tower Holdings, Inc. And Lineage Therapeutics Inc.

-- Acquisitions includes operating subsidiaries CorePharma, LLC and Amedra Pharmaceuticals LLC -- -- Provides Portfolio of Growing, High-Margin, Complex Generic and Branded Products -- -- Enhances...

FDA Grants Priority Review for Genentech's Lucentis in Diabetic Retinopathy

FDA Grants Priority Review for Genentech's Lucentis in Diabetic Retinopathy South San Francisco, Calif. -- October 8, 2014 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),...

Allergan Provides Update on Earnings Per Share and Sales Expectations

IRVINE, Calif., Oct 09, 2014 (BUSINESS WIRE) -- Allergan, Inc. AGN, +0.26% today provided the following updates on earnings per share (EPS) and sales expectations based on current information....

Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.

Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S. PRINCETON, N.J., Oct 08, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY, +0.41% has successfully resolved all outstanding...

Hospira Issues a Voluntary Nationwide Recall of One Lot of Vancomycin Hydrochloride for Injection USP, Equivalent to 1 G Vancomycin (Sterile Powder) Due to Uncontrolled Storage During Transit

Hospira Issues a Voluntary Nationwide Recall of One Lot of Vancomycin Hydrochloride for Injection USP, Equivalent to 1 G Vancomycin (Sterile Powder) Due to Uncontrolled Storage During Transit Contact...

Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting

Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)--Oct. 9, 2014-- Ironwood...

Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion

Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion - Auxilium Shareholders to Receive $33.25 Per Share - Combination Designed to Create Leading...